Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 96Stomach Neoplasms 53Rectal Neoplasms 49Pancreatic Neoplasms 42Colonic Neoplasms 34Esophageal Neoplasms 30Neoplasm Metastasis 28Neoplasms 23Adenocarcinoma Of Esophagus 19Adenocarcinoma 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Lymphoma, Large B-Cell, Diffuse 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Esophageal Squamous Cell Carcinoma 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Liver Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Recurrence 4Lymphoma, Non-Hodgkin 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Bile Duct Neoplasms 4Peritoneal Neoplasms 3Pancreatic Adenocarcinoma 3Leukemia 3Fallopian Tube Neoplasms 3

Interventions

olaparib 1enfortumab vedotin 1Oxaliplatin 1Nivolumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Urothelial Cancer × Oxaliplatin × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡